Author

Luca Paruzzo

Abramson Cancer CenterORCID 0000-0002-6505-0194Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:human· 3 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Marco RuellaiD· 4 shared Federico StellaiD· 2 shared Kai TaniD· 2 shared Patrizia PorazziiD· 2 shared Puneeth GuruprasadiD· 2 shared Stephen J. SchusteriD· 2 shared Vinodh PillaiiD· 2 shared Adam BaggiD· 1 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Marco RuellaORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapies

Quoc Thang Bui, Raghavendra Basavaraja, Mayura R. Dhamdhere, Ágnes Holczbauer, Luca Paruzzo, Puneeth Guruprasad, Michael Scaglione, Yingying Tang, Yu Sun, Daniel P. Beiting, Erik Nash, Hossein Fazelinia, Lynn A. Spruce, Alice Wang, Kai Tan, , Serge Yu. Fuchs

This study identifies SPTBN2 as a regulator of immunosuppressive tumor microenvironment and cross-resistance to therapies, showing its role in suppressing CAR T-cell efficacy.

bioRxiv · Apr 1, 2026 · PreprintCancer Biology

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target

Zhiwei Ang, Annette Castro, Luca Paruzzo, Carolin Schimdt, Zainul S. Hasanali, Katharina E. Hayer, Federico Stella, Samantha S. Soldan, Manuel Torres-Diz, Christopher Kwok, Patricia King Sainos, Kayla W. Ji, Patrick J. Krohl, Justyn Fine, Priyanka D. Sehgal, , Andrei Thomas‐Tikhonenko

The paper identifies P2RX5 as a new B-cell surface marker and multi-lineage immunotherapy target, showing its expression in B-cell malignancies and T-cell leukemia, and demonstrating the efficacy of P2RX5-directed therapies.

bioRxiv · Jan 26, 2026 · PreprintCancer Biology

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies

Alberto Carturan, Mathew G. Angelos, Puneeth Guruprasad, Ruchi P. Patel, Raymone Pajarillo, Andrew Evan Lee, Yunlin Zhang, Wei Xie, Jesse L. Rodriguez, Jaryse Harris, Pooja Devi, Olabisi I. Afolayan-Oloye, Jason Xu, Jonathan H. Sussman, Omar Elghawy, , Marco Ruella

This paper develops anti-CD2 CAR T-cells that overcome fratricide and improve efficacy by incorporating a PD-1:CD2 switch receptor to restore CD2 signaling.

Blood · Jan 5, 2026Peer-reviewedCancer Biology

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells

Tomasz M. Grzywa, Alexandra Neeser, Ranjani Ramasubramanian, Anna M. Romanov, Ryan Tannir, Naveen K. Mehta, Benjamin James Cossette, Duncan M. Morgan, Beatriz Goncalves, Ina Sukaj, Elisa Bergaggio, Stephan Kadauke, Regina M. Myers, Luca Paruzzo, Guido Ghilardi, , Darrell J. Irvine

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.

Nature Biomedical Engineering · Aug 25, 2025Peer-reviewedBioengineering